Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abeona Therapeutics (ABEO) Tops Q1 EPS by 1c
May 11, 2018 8:19 AM EDTAbeona Therapeutics (NASDAQ: ABEO) reported Q1 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19).
Abeona has made significant progress across multiple fronts, including various regulatory achievements, additional enrollments in our MPS IIIA trial, and the reporting of encouraging initial results for our MPS IIIB trial, stated Carsten Thiel, Ph.D., Abeonas CEO. Notably, both our lead clinical programs, EB-101 and... More
